Bizarre Patents
A Receptacle for supporting, rotating and sculpting a portion of ice cream or similarly malleable food while it is being consumed.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7192609 | Use of rare earth compounds for the prevention of kidney stone disease Conditions such as kidney stones, which are characterized by undesired absorption of oxalate from the intestinal tract are conveniently treated using nontoxic salts of rare earth metal ions. ... | 03/20/2007 |
| 7087223 | Preventives and/or remedies for hyperphosphatemia Provided in a phosphate ion adsorbent containing a weakly basic anion exchange resin as an active ingredient which aims at providing preventives and/or remedies for hyperphosphatemia having a high selectivity for the adsorption of phosphate ion and showing an effect... | 08/08/2006 |
| 6887897 | Calcium glutarate supplement and phosphorus binder Methods of controlling calcium intake and phosphate metabolism and metabolic acidosis in patients suffering from renal failure and associated hyperphosphatemia or patients predisposed to development of a hyperphosphatemic condition are provided. The method in accord... | 05/03/2005 |
| 6866651 | Methods and devices for the in situ dissolution of renal calculi Methods and devices for at least reducing the mass of, if not dissolving, renal calculi in situ are provided. In the subject methods, a renal calculus is contacted, e.g. flushed, with an acidic dissolution solution in situ, where the acidic dissolution solution is a... | 03/15/2005 |
| 6613802 | Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia The present invention provides the use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives and compositions in the treatment of insulin resistance, Type 2 diabetes, hyperlipidemia and hyperuricemia.... | 09/02/2003 |
| 6242230 | Process for microencapsulating cells Oxalate-degrading enzymes and bacteria were encapsulated for both enteric and intraperitoneal administration. We have shown that via alginate microencapsulation of Oxalobacter formigenes, enzymatic activity was retained for several months. A new process w... | 06/05/2001 |
| 6033888 | Process for microencapsulating cells Oxalate-degrading enzymes and bacteria were encapsulated for both enteric and intraperitoneal administration. We have shown that via alginate microencapsulation of Oxalobacter formigenes, enzymatic activity was retained for several months. A new process w... | 03/07/2000 |
| 5888986 | Method for treating the urinary bladder and associated structures using hyaluronic acid A method of treating interstitial cystitis comprising contacting the transitional epithelium lining the urinary bladder and associated structures in a mammal having interstitial cystitis with a solution containing hyaluronic acid having a average molecula... | 03/30/1999 |
| 5604103 | Kit for detection of clinical marker in kidney stone disease Dicitrate cyclic diester (dicitrate) is a novel compound which is found in patients who do not exhibit symptoms or predisposition to idiopathic renal calculous disease. Kits are provided for the detection of dicitrate cyclic diester.... | 02/18/1997 |
| 5591724 | Method for treating the urinary bladder and associated structures using hyaluronic acid A method of treating interstitial cystitis comprising contacting the internal bladder and associated structures in a mammal having interstitial cystitis with a solution containing hyaluronic acid having a molecular weight of not less than approximately 2Ã... | 01/07/1997 |
| 5591730 | Inhibition of urinary calculi growth The present invention provides metal ion/bisphosphonate complexes that are useful for the treatment and diagnosis of urinary calculi. Preferred bisphosphonates include etidronate, pamidronate (APD), methylene diphosphonate (MDP), and imidodiphosphonate (I... | 01/07/1997 |
| 5304496 | Biological regulation of mineralization An aspartic acid rich protein isolated from human urine, as well as proteins having substantial homology thereto and active portions of the foregoing are effective modulators of mineralization in mammals. These proteins and peptides are useful as therapeu... | 04/19/1994 |
| 5266595 | Method for treatment of cystinuria A method for treatment of cystinuria which comprises administering to a patient in need thereof an effective amount of bucillamine or a pharmaceutically acceptable salt thereof.... | 11/30/1993 |
| 5234696 | Method of producing tablets, tablets produced thereby, and method of treatment using same Dietetic formulations for oral use are described, made up of tablets formed from dense granules of mixtures of keto- or hydroxy-amino acid analogs, possibly coated by protective films, which are dissolved in the gastrointestinal juices. The process for ob... | 08/10/1993 |
| 5137722 | Extract and pharmaceutical composition for treatment of calcium oxalate stone disease An extract for the treatment of calcium oxalate kidney stone disease which can be extracted and purified from leaves of the plant Eriobotrya japonica is disclosed. The extract has the following characteristics: inhibits calcium oxalate crystal growth in v... | 08/11/1992 |
| 4966776 | Compositions and methods of treating calcium renal stones Methods and compositions useful for the treatment and prophylaxis of calcium renal stones in persons with hypocitraturia or undergoing allopurinol therapy are disclosed. The methods involve administering potassium citrate compositions to persons afflicted... | 10/30/1990 |
| 4931440 | Uricosuric composition The invention relates to a method for preventing and/or treating gout and hyperuricemia which comprises administering a uricosuric effective amount of a quinazoline derivative of the general formula: ##STR1## wherein R1, R2 and ... | 06/05/1990 |
| 4902718 | Calcium homeostasis compositions and methods for controlling calcium metabolism This invention concerns novel calcium normalizing compositions containing as the active agent the amino acid methionine, and/or one or more related compounds including certain metabolic precursor compounds, and novel methods employing the compositions for... | 02/20/1990 |
| 4888182 | Compositions and methods of treating calcium renal stones Methods and compositions useful for the treatment and prophylaxis of calcium renal stones are disclosed. The methods involve administering potassium citrate compositions to persons afflicted with or susceptible to calcium renal stone formations. A typical... | 12/19/1989 |
| 4883791 | 25S,26-dihydroxycholecalciferol in the treatment of hypercalcitriolemic disease states The invention is directed to a method in the treatment of hypercalcitriolemic disease states which comprises administering an effective amount of 25S,26-dihydroxycholecalciferol to a host in need of such treatment.... | 11/28/1989 |
| 4866047 | Method for inhibiting the formation of urinary calculus utilizing 24,25-(OH)2 -D3 Disclosed herein is a method for inhibiting the formation of urinary calculus by the administration of 24,25-dihydroxycholecarciferol.... | 09/12/1989 |
| 4863898 | Amino acid chelated compositions for delivery to specific biological tissue sites Amino acid chelates having a ligand to divalent metal mole ratio of at least 2:1 and having a molecular weight of not more than 1500 and preferably not more than 1000 and also having a stability constant of between about 10 and 10 are formulated for deliv... | 09/05/1989 |
| 4851221 | Liquid calcium supplementation from readily soluble mixtures of calcium compound and citric acid The present invention comprises a composition of matter consisting essentially of citric acid and one or more calcium compounds selected from the group consisting of calcium hydroxide, calcium carbonate and calcium oxide. The composition of matter is pref... | 07/25/1989 |
| 4849452 | Nephro-urological medicament A method of treating nephro-urological disorders, such as kidney stones, phosphate renal calculi formulation, infections connected with urease formation, and abnormal calcium or phosphate excretion is disclosed. The method comprises administration of L-cy... | 07/18/1989 |
| 4845125 | Chemolytic EDTA-citric acid composition for dissolution of calculi An improved composition for dissolution of renal calculi is disclosed. The composition includes citric acid, preferably at about 10 to about 15% by weight, and an effective amount of a pharmacologically acceptable chelating agent such as EDTA in a sterile... | 07/04/1989 |
| 4814177 | Ultradense and more soluble and bioavailable preparations of calcium citrate A calcium citrate composition having a bulk density greater than about 1.1 g/cc. Citric acid and a calcium compound are mixed to produce a mixture having a calcium compound/citric acid molar ratio of about 1.5. A hydrated mixture percent is produced by ag... | 03/21/1989 |
| 4774258 | Treatment of urinary calculi Urinary calculi commonly known as kidney stones are eliminated by the oral administration of triglycine or other suitable chelating agent in amounts appropriate to either the solubilization of preformed urinary calculi and/or to the prevention of the prec... | 09/27/1988 |
| 4772467 | Osteoporosis inhibition by dietary calcium supplementation A process for dietary calcium supplementation. Oral dosage of a composition comprising calcium citrate is utilized to provide an efficiently absorbable chemical form of calcium, while raising urinary level of citrate. Because of improved absorption of cal... | 09/20/1988 |
| 4448786 | 4-Naphthyl and substituted naphthyl-3-hydroxy-3-pyrroline-2,5-diones and their use as inhibitors of glycolic acid oxidase Novel 4-substituted-3-hydroxy-3-pyrroline-2,5-diones are disclosed which inhibit glycolic acid oxidase and thus are useful in the treatment and prevention of calcium oxalate kidney stone formation. A novel process for their preparation is also disclosed.... | 05/15/1984 |
| 4439449 | Medicament for diminution of oxalate development and excretion in urine A method for the treatment of undesired uroliths with benzoic acid is disclosed.... | 03/27/1984 |
| 4432992 | 4-[5(and 4)-Substituted-2-thienyl]-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase Novel 4-[5(and 4)-substituted-2-thienyl]-3-hydroxy-3-pyrroline-2,5-diones are disclosed which inhibit glycolic acid oxidase and thus are useful in the treatment and prevention of calcium oxalate kidney stone formation. A novel process for their preparatio... | 02/21/1984 |
| 4431660 | (4'-Biphenylyloxy and-thio-oxy)-3-hydroxy-3-pyrroline-2,5-diones and a method of treating calcium oxalate renal lithiasis therewith Novel 4-substituted-3-hydroxy-3-pyrroline-2,5-diones are disclosed which inhibit glycolic acid oxidase and thus are useful in the treatment and prevention of calcium oxalate renal lithiasis.... | 02/14/1984 |
| 4431652 | 4-Hydroxy-5-substituted-3(2H)-isothiazolone-1,1-dioxide derivatives useful in treating urinary tract calcium oxalate lithiasis 4-Hydroxy-5-substituted-3(2H)-isothiazolone-1,1-dioxide derivatives of the formula: ##STR1## where X and Y are independently selected from the group consisting of hydrogen, halogen, and C1-6 alkyl; provided that positions 2 and 6 of t... | 02/14/1984 |
| 4428956 | 4-Hydroxy-5-substituted-3-(2H)-isothiazolone-1,1-dioxide derivatives useful in treating urinary tract calcium oxalate lithiasis 4-Hydroxy-5-substituted-3(2H)-isothiazolone-1,1-dioxide derivatives of the formula: ##STR1## where X and Y are independently selected from the group consisting of hydrogen, halogen, and C1-6 alkyl; provided that positions 2 and 6 of t... | 01/31/1984 |
| 4428959 | 4-Alkylsubstituted-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase Novel 4-alkylsubstituted-3-hydroxy-3-pyrroline-2,5-diones are disclosed which inhibit glycolic acid oxidase and thus are useful in the treatment and prevention of calcium oxalate kidney stone formation. A novel process for their preparation is also disclo... | 01/31/1984 |
| 4423063 | 2,4-Dioxo-4-substituted-1-butaoic acid derivatives useful in treating urinary track calcium oxalate lithiasis 2,4-Dioxo-4-substituted-1-butanoic acid derivatives of the formula: ##STR1## where R is hydrogen or C1-4 alkyl; and L is a lipophilic group consisting essentially of ##STR2## where R' is (a) hydrogen; (b) C1-3 alkyl; (c) benzyl... | 12/27/1983 |
| 4377588 | 4-(Substituted thiazolyl)-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase Novel 4-(substituted thiazolyl)-3-hydroxy-3-pyrroline-2,5-diones are disclosed which inhibit glycolic acid oxidase and thus are useful in the treatment and prevention of calcium oxalate renal lithiasis.... | 03/22/1983 |
| 4349561 | 4-Substituted-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase Novel 4-substituted-3-hydroxy-3-pyrroline-2,5-diones are disclosed which inhibit glycolic acid oxidase and thus are useful in the treatment and prevention of calcium oxalate kidney stone formation. A novel process for their preparation is also disclosed.... | 09/14/1982 |
| 4336397 | 2,4-Dioxo-4-substituted-1-butanoic acid derivatives useful in treating urinary tract calcium oxalate lithiasis 2,4-Dioxo-4-substituted-1-butanoic acid derivatives of the formula: ##STR1## where R is hydrogen or C1-4 alkyl; and L is a lipophilic group consisting essentially of: ##STR2## where R1 and R2 are each independently se... | 06/22/1982 |
| 4298743 | 4-(Substituted phenyl thiazolyl)-3-hydroxy-3-pyrroline-2,5-diones Novel 4-(substituted thiazolyl)-3-hydroxy-3-pyrroline-2,5-diones are disclosed which inhibit glycolic acid oxidase and thus are useful in the treatment and prevention of calcium oxalate renal lithiasis.... | 11/03/1981 |
